Mineralys Therapeutics Inc (MLYS) Option Chain

Tracking the MLYS option chain helps you see every strike and expiry on Mineralys Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Mineralys Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of MLYS options activity at a glance. Use our scanner to monitor the MLYS option chain in real time and filter for the MLYS options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For MLYS stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the MLYS option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where MLYS stock options are being actively traded and where they are not.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Mineralys Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen MLYS options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of MLYS stock options — let the full option chain come to you, pre-filtered and ready to trade.